- Viracta Therapeutics Inc To Host R&D Day TranscriptOct 04, 2023
- Viracta Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Viracta Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Viracta Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- Viracta Therapeutics Inc To Discuss Nana-val For The Treatment Of Advanced Epstein-Barr Virus-Positive Solid Tumors Call TranscriptApr 27, 2022
- Sunesis Pharmaceuticals, Inc., Viracta Therapeutics, Inc. - M&A Call TranscriptNov 30, 2020
- Q3 2020 Sunesis Pharmaceuticals Inc Earnings Call TranscriptNov 16, 2020Earnings
- Q2 2020 Sunesis Pharmaceuticals Inc Earnings Call TranscriptAug 11, 2020Earnings
- Q1 2020 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020Earnings
- Q4 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMar 10, 2020Earnings
- Sunesis Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale TranscriptNov 13, 2019
- Q3 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptNov 12, 2019Earnings
- Q2 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptAug 07, 2019Earnings
- Q1 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2019Earnings
- Sunesis Pharmaceuticals Inc at Oppenheimer Healthcare Conference TranscriptMar 19, 2019
- Q4 2018 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2019Earnings
Q1 2019 Sunesis Pharmaceuticals Inc Earnings Call Transcript
Good afternoon, ladies and gentlemen, and welcome to the Q1 2019 Sunesis Pharmaceuticals, Inc. Earnings Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Willie Quinn, Chief Financial Officer and Senior Vice President, Corporate Development.
Thank you all for joining us. With me today are Dayton Misfeldt, Interim Chief Executive Officer; Judy Fox, Chief Scientific Officer; Par Hyare, Vice President, Global Oncology Operations; and Deepali Suri, Vice President, Clinical Operations.
Dayton will review recent corporate events, Judy will provide more details on the vecabrutinib program and I will provide a brief financial overview of the first quarter 2019. We will then open the call for questions, for which we will all be available.
Before we begin, let me remind you that during today's conference call, we will be making
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)